Good morning, and welcome to the Manulife Financial Fourth Quarter and Full Year 2021 Financial Results Conference Call. Your host for today will be Mr. Hung Ko. Please go ahead, Mr. Ko. Thank you. Welcome to Manulife's earnings conference call to discuss our fourth quarter and year-end 2021 financial and operating results. Our earnings release, financial statements, and related MD&A, statistical information package and webcast slides for today's call are available on the Investor Relations section of our website at manulife.com. Turning to slide four. We will begin today's presentation with an overview of our fourth quarter and year-end highlights and an update on our strategic priorities by Roy Gori, our President and Chief Executive Officer. Following Roy's remarks, Phil Witherington, our Chief Financial Officer, will discuss the company's financial and operating results. After the prepared remarks, we will move on to the live question-and-answer portion of the call. We ask each participant to adhere to a limit of two questions, including follow-up questions. If you have additional questions, please re-queue, and we will do our best to respond to all questions. Before we start, please refer to slide two for a caution on forward-looking statements and slide 43 for a note on the non-GAAP and other financial measures used in this presentation. Note that certain material factors or assumptions are applied in making forward-looking statements and actual results may differ materially from what is stated. With that, I'd like to turn the call over to Roy Gori, our President and Chief Executive Officer. Roy. Thanks, Hang. Thank you everyone for joining us today. Yesterday, we announced our fourth quarter and full year 2021 financial results, and I'm incredibly proud of our performance. You'll see on slide six, we delivered record core earnings of CAD 6.5 billion in 2021, a 26% increase from the prior year, with double-digit growth in our Global WAM business. We also reported record net income of CAD 7.1 billion, an increase of CAD 1.2 billion over the prior year. We continue to focus on growing our customer base and serving our customers' evolving needs better, which is evident in our new business value increase of 31% to CAD 2.2 billion with double-digit growth across all segments. This was a particularly strong result given the COVID-19 restrictions in markets in which we operate in Asia, such as Vietnam and the Philippines. In addition, NBV margin for Asia increased by 6.1 percentage points from the prior year, reflecting both benefits of scale and favorable product mix. In our Global WAM business, we achieved strong net inflows of CAD 27.9 billion, triple the prior year level, primarily reflecting continued strong growth in our retail business across all geographies. 2021 was a record year for our retail wealth business, with net inflows of CAD 29.2 billion. In addition, we delivered very strong remittances of CAD 4.4 billion, a CAD 2.8 billion increase from the prior year. Turning to slide seven 2021 was not without its challenges. Despite the headwinds, we generated strong growth on a full year basis. Notably, when compared to pre-pandemic, our top line growth and Global WAM net flows exceeded our 2019 results, demonstrating the long-term strength of our franchise. The diversity in our business was a crucial factor in delivering strong financial performance in 2021, as seen in our record core earnings and net income, as well as strong growth in new business value. Our presence in 13 markets in Asia demonstrated the benefits of geographic diversification as strong top-line growth in Hong Kong, Singapore, and Vietnam balanced the impacts of COVID-19 and regulatory changes in China, Japan, and other emerging markets. We also gained share in five markets during 2021. Our U.S. business growth continued sales momentum, with sales ahead of prior year in almost every major category. We also reported record sales in our international business. In Global WAM, one of our growth engines achieved double-digit growth in earnings and tripled its net inflows. In the fourth quarter, we announced a dividend increase of 5 cents per share, resulting in a total quarterly common shareholders dividend of 33 cents per share, or an 18% increase. This increase resumed our track record of sustained gradual dividend increases, which remains one of our top capital deployment priorities. We also recently launched a normal course issuer bid to repurchase up to 5% of outstanding common shares. Turning to slide eight. We are laser-focused on delivering on our strategic priorities and the 2025 supplemental goals that we announced at our recent investor day. Our results this year are a testament to that commitment. Our highest potential businesses accounted for 63% of total company core earnings in 2021, and we're on track to achieve our target of two-thirds by 2022. We aspire to have core earnings from the Asia region contribute 50% by 2025. In 2021, amid the challenges of COVID-19 in select markets, core earnings from the Asia region contributed 39% of total company core earnings. We're scaling our business to grow across the diverse markets in Asia. For example, in December 2021, we launched a 16-year exclusive bank insurance partnership with VietinBank, one of the largest financial institutions in Vietnam. This partnership significantly enhances our distribution capability in Vietnam to offer a full suite of insurance, wealth, and retirement solutions to a significant percentage of the Vietnamese population. With this transaction, we also acquired Aviva Vietnam, which further enhances our scale in this important and growing market. I'll speak more on this exciting development in a moment. Our Global WAM business expanded the retail product lineup beyond traditional mutual funds with new actively managed exchange-traded funds in both Canada and the U.S. We furthered our separately managed accounts offering in the U.S., with each category generating over $1 billion in net inflows in 2021. In the U.S., we achieved record sales of products with the market-leading John Hancock Vitality PLUS feature. We believe that our Vitality offering, which focuses on rewarding customers for healthy living, is not only the right solution but resonates with customers as they focus more on well-being and improving quality of life. Our ambition is to be a leader in our industry when it comes to digital capabilities and customer experience. We're executing on our strategy to attract, engage, and retain customers by delivering an outstanding experience with every interaction. During the year, we continued to make progress on our digital journey across all our operating segments. This played a significant role in our ability to listen to our customers, adapt, and leverage our digital capabilities to better serve our customers across the globe. Our continued investments in digital enhancements have contributed to our significant Net Promoter Score improvements. In 2021, we achieved a score of +21, which is a 20-point improvement from the 2017 baseline and a nine-point improvement from 2020. In 2021, we achieved straight-through processing of 82%, and we're on track to achieve our supplemental goal of 88% by 2025. In Asia, ePOS, our digital onboarding app, is supporting our agents with faster, higher quality new business submissions. Throughout the year, 82% of applications were submitted digitally, representing an increase of 22% year-over-year, and 79% of these applications were auto-underwritten. In the U.S., we completed the iPipeline integration with the JH Brokerage eApp. This integration provides the majority of our regular distribution partners with access to next-generation sales tools and decreases the overall cycle time for applications submitted via this preferred channel by 49% year-over-year. It also enabled access to over 250 firms, including a new partnership with Allstate and its more than 11,000 agents. These initiatives contributed to a 15 percentage point increase in overall new business applications submitted digitally in 2021 to 71%. In our Global WAM U.S. retirement business, 88% of plan participants enrolling have adopted our new digital express enrollment capability that delivers a simple, fast, and seamless way to enroll in their plan and benefit from access to personalized guidance. This resulted in an 11% increase in participation and six times the managed accounts conversion rate when compared to the previous enrollment process. Turning to slide 9. We've now commenced our partnership with VietinBank to establish an exclusive 16-year bancassurance partnership to better meet the growing financial and insurance needs of the Vietnam market. To make the lives of millions more of Vietnamese better every day. VietinBank is one of Vietnam's largest financial institutions, and this partnership provides us with exclusive access to more than 14 million customers through a network of over 150 branches and 1,000 transaction offices across 63 cities and provinces. Partnering with VietinBank accelerates our growth trajectory in the region, further strengthening our leadership position in Vietnam's fast-growing market and solidifying our position as a leader in insurance and wealth management. We expect the opportunities generated by this exclusive partnership to result in an immediate accretion to our earnings in the first year. Turning to slide 10. I want to take a few minutes to highlight our tremendous success story in Vietnam even before this exciting new partnership. Our APE sales and new business value have grown rapidly from 2017 to 2021 at a compound annual growth rate of 27% and 51% respectively. These are impressive results considering the impact of COVID-19 restrictions during 2020 and 2021. This tremendous growth was powered by our professional agency force and a market-leading bancassurance distribution channel that propelled our market ranking from number four in 2017 to the number one position, which we've held since 2019. Our bancassurance channel is anchored by our exclusive partnerships with Saigon Commercial Bank, Techcombank, and now VietinBank, which gives us access to 24 million bank customers. Vietnam has significant growth potential with one of Asia's highest GDP growth rates, a high proportion of working age population, and life insurance penetration rates that are well below other emerging and developed markets in Asia. Looking forward, our focus will be on further expanding and professionalizing our agency platform, deepening customer penetration with our bank partnerships, enhancing digital capabilities for key customer and distributor touchpoints, and finally, further automating processes to harness the benefits of our scale. Turning to slide 11. Expense efficiency is deeply embedded in our culture. In 2021, our expense efficiency ratio improved by 4 percentage points, and we have achieved our target of less than 50%. We remain focused on driving efficient growth and are committed to consistently achieving an expense efficiency ratio of less than 50% going forward while ensuring scalable growth, outstanding customer experience, and digital ways of working. Phil will discuss our progress in more detail. Turning to portfolio optimization. On a cumulative basis, we freed up CAD 6.3 billion of capital through various efforts across multiple legacy blocks. Our commitment and focus on optimizing our long-term care and variable annuity businesses is as strong as ever. We aim to achieve our 2025 supplemental goal of reducing core earnings contributions from these businesses to less than 15% of total core earnings and would like to see this decline further to less than 10% with inorganic actions. I'm pleased to report that in 2021, we reduced the core earnings contribution from our long-term care and variable annuity businesses to 20%, supported by the increasing contributions from our highest potential businesses. In addition, we entered into an agreement in the fourth quarter to reinsure a significant portion of our legacy U.S. variable annuity block with Venerable Holdings, Inc. I'm pleased to confirm the transaction closed on February 1st, and it's expected to result in approximately $2 billion of capital released in 2022. This transaction positions us well to achieve our 2025 supplemental goal. I will go into a bit more detail on this transaction in a minute. Our fifth priority is focused on our high-performing team. We recently completed our 2021 employee engagement survey and maintained a top quartile position, ranking in the 86th percentile amongst global financial services and insurance peers. Also in October, Manulife was named a world's best employer by Forbes for the second year in a row. Turning to slide 12. I'm pleased with the successful completion of the U.S. VA reinsurance transaction on February 1st. This transaction represents a significant milestone for Manulife, greatly lowering our go-forward risk profile while reducing our exposure to the U.S. VA guaranteed value and net amount at risk. It reduces our equity market sensitivity from our variable annuity guarantee by roughly 54%. We have unlocked significant shareholder value with an estimated CAD 2 billion of expected capital release, which includes an after-tax gain of approximately CAD 750 million, validating the conservatism of our reserves. This represents a strong multiple of more than 10x earnings. We plan to deploy a significant portion of the capital release to buy back common shares to neutralize the impact of the transaction on core EPS. We remain committed to optimizing our legacy portfolio, especially LTC and VA, and will continue to seek opportunities to reduce risk and unlock value. Turning to slide 13. I'm incredibly proud of the way our colleagues around the world have continued to make decisions easier and lives better for our customers throughout 2021. We delivered record results in 2021, underpinned by double-digit growth in Asia and global WAM. We've commenced the 16-year bancassurance partnership with VietinBank and acquired Aviva Vietnam, which further accelerates our growth in one of the most exciting markets in Asia. While we've achieved our expense efficiency ratio target of less than 50%, we remain focused on driving efficient growth as we look forward. We executed on optimizing our legacy business by completing the U.S. VA reinsurance transaction, which unlocked value for shareholders and reduced risk. We continued to deploy capital by increasing the quarterly dividend by 18% in the fourth quarter and commenced share buybacks under the recently launched NCIB program. Our solid foundation, global presence, diverse business, and continued strong execution uniquely positions us to succeed and deliver on our growth targets. Thank you. I'll hand over to Phil Witherington, who will review the highlights of our financial results. Phil? Thanks, Roy. Throughout 2021, we continued to execute on our strategic priorities, and we delivered strong operating and financial results with record core earnings and net income. Our fourth quarter metrics were similarly impressive. I will highlight the key drivers of both our fourth quarter and full-year performance with reference to the next few slides. I'll start on slide 15. We generated strong core earnings of CAD 1.7 billion in the fourth quarter of 2021, up 20% from the prior year quarter. This growth was driven by a number of factors. The recognition of core investment gains in the quarter, higher net fee income from higher average AUMA in our Global WAM business, higher new business gains in the U.S. and Canada, a decrease in the corporate and other core loss which benefited from a lower cost of debt and higher investment income, and double-digit in-force business growth in Canada and Asia. These items were partially offset by unfavorable policyholder experience and lower net gains on seed money investments. Net income attributed to shareholders of CAD 2.1 billion in the fourth quarter was up 19% from the prior year quarter, reflecting growth in core earnings and gains from the direct impact of interest rates compared with losses in the prior year, partially offset by lower investment related experience gains and lower gains from the direct impact of equity markets. Of note, we recognized a gain of CAD 226 million from investment related experience in the fourth quarter of 2021, reflecting higher than expected returns on OLVA, primarily driven by fair value gains on private equity and infrastructure, as well as strong credit experience. These items were partially offset by the unfavorable impact of fixed income reinvestment activities, primarily driven by the acquisition of U.S. Treasury bills. CAD 100 million of these gains were reported in core earnings as core investment gains, with the remaining CAD 126 million reported outside of core earnings. The gain of CAD 274 million from the direct impact of interest rates was due to the flattening of the yield curve in Canada and the U.S., as well as gains from widening corporate spreads in the U.S., partially offset by the realization of losses from the sale of AFS bonds. The impact of equity markets in the quarter was a gain of CAD 124 million. Slide 16 shows the performance of our older portfolio by asset class since the acquisition of John Hancock 17 years ago. The average return of the overall portfolio during this period was 9.4%, outperforming our current best estimate long-term return assumption of 9.2%. We're pleased with the strong performance of the portfolio in 2021, that not only recovered from prior-year losses, but also contributed to the CAD 1.25 billion of total investment related experience gains over the past two years, which exceeded our core investment gains of up to CAD 400 million per year or CAD 800 million over two years. Slide 17 shows our source of earnings analysis for the fourth quarter of 2021 compared to the prior-year quarter. Expected profit on in-force increased 8%, driven by in-force business growth in Canada and Asia. New business gains increased 21% from the prior year period, driven by higher sales volumes and improved margins in the U.S. segment from our domestic and international high net worth businesses, higher sales volumes and favorable product mix in individual insurance in Canada, and higher sales volumes and the favorable impact of product repricing in Hong Kong. This was partially offset by lower critical illness sales and margins in China, lower sales amid continuing COVID-19 restrictions and unfavorable product mix in Vietnam, lower COLI sales in Japan, as well as lower sales volumes in several emerging markets that were impacted by COVID-19 containment measures. The experience loss in the quarter was primarily driven by unfavorable policyholder experience due to elevated mortality levels, particularly in U.S. Life, continued low lapse rates on North American protection products, and a modest charge in Asia, driven by unfavorable claims, partly due to COVID-19 and persistency losses. Canadian Group Insurance was neutral and long-term care policyholder experience was a modest gain. Slide 18 shows a history of our policyholder experience, excluding the charges related to Hurricane Ida and the European floods in 2021. The pandemic and related macroeconomic environment impacted our policyholder experience differently across product lines. The diversity of our businesses and our use of reinsurance provided an offset between these experiences, and on a cumulative basis over 2020 and 2021, reduced the impacts to a net charge of less than CAD 30 million post-tax. Slides 19 and 20 show our earnings by segment and return on equity. I will comment on the fourth quarter results compared with the prior year quarter. We delivered core earnings growth of 30% in our Global WAM business, reflecting growth in net fee income driven by higher average AUMA that benefited from the favorable impact of markets and net inflows, as well as favorable business mix and higher tax benefits. Core earnings in Asia was consistent with the prior year, as in-force business growth was offset by modestly unfavorable policyholder experience, which included COVID-19 related claims losses, lower new business gains, and lower investment income on allocated capital. Core earnings in Canada decreased by 9% as less favorable policyholder experience in group insurance, lower investment income on allocated capital, and the non-recurrence of a release of tax provision in the fourth quarter of 2020 were partially offset by higher expected earnings across all businesses and higher individual insurance sales. Core earnings in the U.S. increased by 1%, reflecting new business gains from higher sales and improved margins, partially offset by lower investment income on allocated capital, lower but still favorable long-term care policyholder experience, and lower tax benefits. The core loss in corporate and other improved by CAD 217 million, primarily driven by the recognition of core investment gains in the quarter, compared with nil core investment gains in the prior year quarter, lower interest on allocated capital to operating segments, lower interest on external debt, and higher investment income and gains on sales of AFS equities. These gains were partially offset by the unfavorable impact of markets on seed money investments, compared with gains in the prior year. We delivered core ROE of 12.7% in the fourth quarter and 13% for 2021. Turning to slide 21, which shows our new business value generation. In this uncertain environment, we have adapted to better serve our customers across the globe, resulting in the double-digit growth in our NBV in 2021. In the fourth quarter of 2021, we delivered new business value of CAD 555 million, up 17% from the prior year quarter. In Asia, NBV increased 11% from the prior year quarter, reflecting higher sales volumes, favorable interest rates, and disciplined expense management in Hong Kong, as well as favorable product mix in Asia Other, partially offset by lower sales in Japan and China. In Canada, NBV increased 26% from the prior year quarter, primarily due to higher margins in annuities and higher volumes in individual insurance. In the U.S., NBV increased 51% from the prior year quarter, primarily driven by higher sales volumes and favorable product mix, notably from our international business, which is reported as part of the U.S. segment. On a full year basis, NBV grew at a double-digit rate compared with both the prior year and the pre-pandemic level in 2019. Our Asia business generated the majority of total NBV of the company and delivered a growth of 27% in 2021 compared with the prior year, reflecting the diversity and distribution strength of our franchise, which also allowed us to gain share in various markets across the region. Slide 22 shows our APE sales. In the fourth quarter of 2021, we delivered APE sales of CAD 1.4 billion, a 5% increase from the prior year quarter. Asia APE sales declined by 6%. In Hong Kong, APE sales increased 11% despite the effect of COVID-19 containment measures that continued to constrain cross-border travel between Hong Kong and mainland China. The increase in APE sales reflects strong growth in our bank channel and demand from mainland Chinese visitors through our Macau branch. Asia Other APE sales were in line with the prior year quarter as expansion in the bank insurance channel was offset by lower agency sales, which were adversely impacted by COVID-19 containment measures in markets such as Vietnam and the Philippines. The growth in Hong Kong and overall stability of Asia Other markets was more than offset by a 44% decline in Japan COLI sales, reflecting a continuation of the trend seen in previous quarters. In Canada, APE sales increased by 20%, primarily driven by increased customer demand for our lower risk segregated fund products and higher individual insurance sales. In the U.S. segment, APE sales increased by 41% due to strong customer demand for our international high net worth solutions and our differentiated domestic product offerings, which include the John Hancock Vitality feature. For 2021, overall APE sales grew at a double-digit rate compared with the prior year and also exceeded the pre-pandemic level in 2019. Turning to slide 23. Our Global WAM business continued to benefit from our geographic and line of business diversification, as evidenced by strong net inflows of $8.1 billion and gross flows of $36 billion in the fourth quarter. In retail, net inflows were $7.5 billion, compared with net inflows of $3.6 billion in the prior year quarter. The increase reflects strong intermediary sales and higher institutional model allocations in the U.S., as well as higher gross flows in Japan and China. Institutional asset management net inflows were $1.6 billion, compared with net inflows of $1 billion in the prior year quarter. The increase was driven by lower redemptions in timberland and real estate mandates, partially offset by lower gross flows in fixed income mandates. During the fourth quarter, we continued building out our private markets business with the successful fundraising of approximately $7 billion on two funds, with commitments from both third-party investors and Manulife's general account. Approximately one quarter of the fundraising from third-party investors has been deployed and reflected in our AUM, with the remainder to be deployed over the next several years. In retirement, net outflows were CAD 1 billion, compared with net outflows of CAD 1.8 billion in the prior year quarter. The reduction in net outflows was driven by higher gross flows across all geographies, reflecting higher growth in new plan sales and member contributions, partially offset by higher plan redemptions. Close to CAD 0.6 billion of the retirement outflows were captured in our retail net inflows as we rolled over plan participants to our retail platforms. We continued to see strong net inflows in the Hong Kong MPF business, retaining our number one market rank by assets under management and net flows. Overall, Global WAM's average AUMA increased by 17% in the fourth quarter compared with the prior year quarter, driven by the favorable impact of markets and higher net inflows. Turning to slide 24. Net fee income yield remains resilient, reflecting our diversified business mix. Our core EBITDA margin increased 70 basis points, driven by a combination of higher net fee income, operational benefits from increased scale, and continued disciplined expense management. Turning to slide 25. In 2021, we achieved annual savings of CAD 100 million resulting from the restructuring announced in the first half of the year. Our culture of expense efficiency has resulted in a modest growth of 5% in core general expenses in 2021, which was far outpaced by the 25% increase in pre-tax core earnings. This contributed to a 4 percentage point decrease in our expense efficiency ratio to 48.9% in 2021. As Roy mentioned, we have achieved our target of less than 50%. We remain focused on driving efficient growth and are committed to consistently achieving an expense efficiency ratio of less than 50%, with scalable operations to support growth and digital tools to provide an outstanding customer experience. Turning to slide 26. We continue to maintain a strong balance sheet and capital position. We have CAD 27 billion of capital above the supervisory target, and our LICAT ratio of 142% is strong. The 4 percentage point increase compared with the third quarter was driven by a net capital issuance and favorable market movements, primarily from lower risk-free rates. Our financial leverage ratio increased 0.3 percentage points, driven by the net capital issuance, largely offset by growth in retained earnings and an increase in the value of AFS debt securities. I would note that we have recently announced our intention to redeem CAD 725 million of preferred shares. The impact of these redemptions will be reflected in the LICAT and leverage ratios for the first quarter of 2022. Adjusted for these redemptions, the pro forma LICAT and leverage ratios would be 141% and 25%, respectively. Turning to slide 27 and our financial performance for the fourth quarter and full year 2021. As mentioned, in 2021, we delivered double-digit net income, core earnings, NBV, and APE sales growth, and achieved strong net inflows in our Global WAM business. Our strong balance sheet, as evidenced by our LICAT and leverage ratios, provides us with financial flexibility to deliver on our strategic and capital deployment priorities. Remittances increased by CAD 2.8 billion to a total CAD 4.4 billion in 2021, with positive contributions across all geographies. We continued to execute on our capital deployment priorities, including a strong track record of delivering progressive dividend increases. We're pleased to have made an 18% increase in our quarterly common share dividend in the fourth quarter, which combined the annual increase for 2021 with an accelerated annual increase for 2022. In addition, we will be deploying capital to buy back shares under the recently launched NCIB program of up to 5% of outstanding common shares to generate shareholder value and to neutralize the impact on core EPS from the U.S. VA reinsurance transaction. Slide 28 outlines our medium-term financial targets and recent performance. We're pleased with our strong results in 2021, which met or exceeded most of our medium-term targets. Core EPS growth of 18% exceeded our target, while core ROE was in line with target and the dividend payout ratio remains within our target range. The leverage ratio was modestly above target, but would be at 25% after adjusting for the announced preferred share redemptions. This concludes our prepared remarks. Operator, we will now open the call to questions. Thank you. We'll now take questions from the telephone lines. If you have a question and you're using a speakerphone, please mute your handset before making your selection. If you have a question, please press star one on your device's keypad. To cancel the question, please press star two. Please press star one at this time if you have a question. There will be a brief pause while participants register. Thank you for your patience. The first question is from Scott Chan from Canaccord Genuity. Please go ahead. Oh, thank you very much. Good morning. So just on the rate environment, a lot has changed over the last 2-3 months in terms of the futures market pricing, both in U.S. and Canada. I think five rate hikes for both in 2022 is consensus. Like outside the negative impact to the LICAT ratio, can you kinda talk about and remind us kind of the puts and takes or positives on the changing rate environment that we could see this year? Yeah, thanks for that question, Scott. Roy Gori here. I'll start, and I'll ask Phil to chime in with some thoughts from his perspective. Obviously, higher inflation often translates into higher interest rates, and that is generally a positive for our organization. I'll remind everyone that a 50 basis point increase in fixed income market yields translates into a positive PV improvement of CAD 1.85 billion in embedded value. Now, clearly there are some puts and takes, and the negatives of higher inflation is that you have higher costs and expenses. For our organization, we've been very focused on driving the benefits of scale and digitizing our business, which has translated into us improving our efficiency quite significantly over the last few years and achieving our less than 50% efficiency target in 2021, which we believe again will be a tailwind for us as we look to 2022 and beyond. Again, there are puts and takes, but I would just generally conclude that higher rates are a positive for us. They're a bit of a tailwind. There are some aspects of our business where higher rates will create some headwinds, but we have flexibility as it relates to driving scale through expenses or price changes to offset those. Generally, we think that that's a positive for us. Phil, you may wanna supplement. Sure. Thanks, Roy, and thanks for the question, Scott. The only point that I would supplement there is that whether rates go up or go down, much of our portfolio is now either participating or pass through. What that means is that we are to some extent insulated from the liability impact. We're able to share that with our policy holders. In some cases, the same is true with inflation as well. We do see that correlation between interest rates and inflation. That's what's playing out in the current environment. Okay. Just my second question. If I look at Manulife Bank core earnings, it was down for the first time in a while. I think it was down quarter-over-quarter and 17% year-over-year, where we see all bank earnings being positive in this environment. I see the assets go up quarter-over-quarter, but just wondering if there was any drivers of that, and then any decline that you can call out. Yeah. Hi, Scott. It's Mike Doughty. On the bank, there was in Q4 of last year an accounting policy change, which didn't reoccur this year. That was primarily the drop in the fourth quarter. Over the course of the year, the bank actually did grow. That was largely driven by the release of credit provisions that we had set up in the previous year, some equity gains that we got off of good markets, and then offset by you know, net interest compression that we experienced during 2021. Got it. Thanks for that. Thank you. The next question is from Meny Grauman from Scotia Capital. Please go ahead. Hi. Good morning. A little bit of a bigger picture question. There's been a lot of ink spilled over the last little while on Hong Kong, population declines there, brain drains, expats leaving, locals fleeing. I'm just wondering, obviously, you know this market very, very well. It's an important market for you. What's your perspective there and the impact or the potential impact on your business there? Thanks for the question, Meny. This is Anil Wadhwani here. If you look at our Hong Kong business, it has been exceedingly resilient and strong, despite some of the challenges. You can go back to 2019. If you look at our last 17 quarters, we have been able to deliver positive core earnings growth in Hong Kong, year-on-year for the last 17 quarters. Even if you were to kind of simply look at our quarter four earnings in Hong Kong, or for that matter, full year earnings in Hong Kong, we were able to deliver 17% growth on the back of a 32% new business value growth in that market. This pretty much kind of underscores a few things. It underscores the quality of our franchise and the way we have been investing in expanding our distribution, our digital and our people capabilities. It also kind of underscores our execution capabilities. As a consequence of that, and Phil mentioned that in his opening remarks, we have been able to gain market share for consecutive years in this important market. Our driver-based agency now stands at over 11,600. Our partnership with DVS and brokers has never been stronger. We feel very confident that Hong Kong is well-positioned to be able to navigate some of the headwinds, as we have demonstrated now for a few years. Additionally, Hong Kong will benefit from the opening of borders, and with the greater velocity of mainland Chinese visitor customers, as well as initiatives like GBA. That's going to result into further acceleration of the movement of resources and capital. Hong Kong and Macau, where we have a very strong distribution, we are likely to benefit from that. Thanks for that. Maybe just as a related question, just if you could update us on the COVID environment in the Asia region, how you're seeing that play out in terms of your business. We're seeing, obviously, lockdowns in Hong Kong intensify. I'm just wondering if you go across your key markets, are there any areas where we should expect an improvement in Q1 in particular? Sure. Thanks for the question once again, Meny. As I said, our results have been quite resilient, and we have been working with the backdrop of COVID now for a couple of years. In light of that, our results both in quarter four as well as for the full year 2021 have been quite resilient. Now, obviously, the onset of Omicron kind of creates a bit of uncertainty, and that makes it a little bit hard for us to kind of predict given the fact that it's unknown as to how the spread as well as the containment measures are going to pan out in the different geographies. You know, what our strength has been is the diversified nature of our markets. That's really been a source of strength for us and a key contributor to the way we've been able to navigate some of the headwinds over the last couple of years. This might kind of pose a challenge or two for us in the short term, but given the secular trend, given the under-penetration in Asia, the demand for protection and retirement products is quite undeniable. Again, given our market-leading positions in many of the significant geographies, we are very well positioned to be able to address that opportunity. Hey, Meny, it's Paul Lorentz here. I just wanted to add a couple comments from the Global Wealth and Asset Management side, because while Anil had commented from an insurance perspective, our platforms that we have in Asia have really been able to kind of weather through the COVID impact. We haven't seen a material impact on our wealth and asset management business, and the flows have been quite strong, even with just because of the digital platforms we have there and the reach. To your first question, from a retirement perspective, we haven't seen a material impact at all from the immigration concerns that you mentioned, nor do we expect it to have an impact on our retirement business. In fact, 2021 was our best year ever. Our flows in AUM increased year to date versus prior year. They were both faster than the market. Our net flow market share was 48%, and our AUM market share was 27%, which was up from 24.6% the year before. We actually think we're really well positioned, particularly as immigration picks up and comes back calm, that we've got just such a great franchise there that will benefit over time. Got it. Thank you, Paul. Thank you. The next question is from Humphrey Lee from Dowling & Partners. Please go ahead. Good morning, and thank you for taking my questions. To stay with a question with Paul, looking at the Global WAM, retail flows were really strong. This is actually surprising given many of your asset manager peers had sizable outflows due to rebalancing. I was just hoping if you can provide a little bit more color in terms of the geographies and the products that you're getting the inflows and how should we think about kind of the outlook for 2022? Yeah. Thanks, Humphrey, and it's Paul here. We're really pleased with the flows and the continuing momentum we've been driven for the business. You mentioned retail. I'll start with that. We had CAD 7.5 billion in flows in retail. A lot of that growth was driven by pretty much all regions, contributed to the strength. I'll start with the U.S., though. The U.S. definitely was the biggest contributor, was our sixth consecutive quarter of positive net flows. What we're seeing there is continued strength into our fixed income franchise, particularly core fixed income. We also saw a rotation to value last year, and we have a very strong lineup as it relates to some of our value-focused equity funds, and so we're benefiting from that. Canada continues to drive, you know, strong net flows for the franchise. We've got a very strong performing platform there. I think we've been recognized three years in a row with the top-performing fund platform. In Asia, we saw very strong growth, as I just mentioned, particularly in the retail platform relative to our size last year. Our net flows in Asia relative to our AUM I think were close to 40%. We saw very strong flows in Asia across the board. Just in terms of what's selling in some of those outside of the U.S., we've got pretty balanced franchise in Canada. As you would have seen in the asset mix, we started to see more equity flows and balanced flows, and you would see that through the change in our asset mix from about a year ago. We feel really good about just the strength of the retail franchise, our overall performance and our distribution reach, and then the fact that the contribution's coming from all three regions. The only other comment worth noting, and Phil mentioned this because we shared this at Investor Day, is we also saw some success in our private markets business on our institutional channel in the fourth quarter with the closing of two funds, our Manulife Infrastructure Fund II and our private equity Manulife Co-Investment Partners Fund II. And again, not all of those flows are reflected. About a quarter of that is reflected in the AUM. We do expect as that money gets invested in the coming years, that will also show up. We're really feeling really good just about the diversification of our business by channel, by platform, the broad base of what we have to offer to investors, and the overall quality of the investment performance that the teams deliver. The 40% of AUM inflows in Asia was really impressive. I guess is it a result of adding distributional channel or what's the driver for getting that level of inflows? Yeah. It's a combination of just continued expansion in terms of the types of products and distribution reach that we have. We are seeing really strong progress through our digital platforms. We launched a digital platform called iFunds in Asia, in a number of markets, and that's leveraging our insurance segment distribution, our life agents. It's a complete end-to-end digital platform for consumers to access our lineup there, and it integrates the advisor into that process. We're seeing some really solid growth in a number of markets in an area we continue to invest in. Got it. Thank you. Thank you. The next question is from Doug Young from Desjardins Capital Markets. Please go ahead. Hi. Good morning. Just back to Anil. I think two areas where you've had some weakness in Asia is Japan and China, and I think both related to regulatory changes that have occurred over the last little while. What I'm hoping to get is some just an update in terms of, you know, the launch of new products in Japan as a result of the change around the COLI product. And in China, just some of the changes that have made around the regulatory side that have impacted sales and core earnings. Can you give us a bit of an update where you stand? Like, what inning are we in in terms of turning those around? A great question, and I'll be happy to answer that, and thanks for that. Let me start with Japan first. As we have indicated in the past, our primary focus in Japan has been on inforce and on expense efficiency, and you kind of seen that translated to a 9% core earnings growth in quarter four in Japan, and for the full year, a growth of 7%. We have directed our resources to some of our high growth markets, for example, in Asia Other. Asia Other today contributes to 36% of our core earnings as opposed to 16% of our core earnings back in 2015. On an ongoing basis, our emphasis in Japan will be value maximization through our focus on inforce and expense efficiency. We will parallelly also, we are making efforts to change our product mix away from COLI, to drive better product mix on other wealth and retail. Again, we are starting to see significant progress on that in Japan. With respect to China, we delivered a 12% growth on sales and 14% on new business value. Given the backdrop of what you mentioned, the regulatory changes as well as COVID, we thought that was a very creditable performance. There are a few things going on in China. Again, on regulatory front, there are a couple of things that we are obviously navigating. Firstly, on account of the regulatory changes that impacted the critical illness product that were announced in quarter one of last year, the industry has seen a contraction of demand on critical illness, and that has led to a different product mix, which obviously has a knock-on impact then on new business gain, as well as on a new business value. While we believe that these changes are good for the sustainable growth, they do require a bit of an adjustment in the shorter term. What we are also witnessing in China is a very strong growth on retirement needs that will go and sit on top of some of the protection needs that we believe will rebound in the medium term. The second piece of change that we're seeing in China is the regulators are getting increasingly focused on driving quality agency distribution, and that is squarely in line with the way we would like to grow our distribution. Just to kind of give you a stat, the industry is witnessing a decline of roughly about 30%-35% on agency. In contrast to that, we are witnessing a 15% decline. I think as the market evolves and we make the necessary adjustments, I think quality distribution is gonna hold us, you know, in good stead for quality growth in China. Now, we have access to 52 cities across 15 provinces. We have a very strong joint venture partner. The under-penetration in China and the secular trends will be positive to drive growth. Yes, in the medium term, we believe that China will still remain an accelerator of growth for us, as we transition to the new landscape in that market. It sounds like China has kind of hit the inflection point. Maybe my question around Japan is Japan turning into a closed block? Is that the way to think of it? I don't know if that's for you, Anil, or for Roy. I'm gonna start off, and then I'll ask Roy to add his comments. We believe that our focus is gonna be, as I said, on driving a different product mix. If you were to kind of go a year back, COLI was 50% of the sales mix. COLI is now less than 10% of our sales mix. Now what this does is it also helps us improve our new business value margin, which you can see in our quarter four results in Japan. Now on top of that, as I said, our efforts of in force management as well as expense efficiency is resulting into the core earnings growth that we are witnessing. We feel that in Japan, we also have an opportunity to drive a product mix with a higher margin away from COLI as opposed to what we have been doing in the past. Ron? Yeah, I'll just add, Doug, that Japan is clearly still a very important market for us and a market that provides a lot of opportunities. The third-largest insurance market in the world. We've operated in the market for a long period of time, which has allowed us to establish a really strong and credible brand. Over the years, we've improved our margins quite considerably. As Anil highlighted, there are some regulatory pivots that we're navigating. We see them as short term from a headwind perspective. In the medium to longer term, we still feel very positive about the opportunities that Japan represents. As Anil highlighted, you know, we're gonna continue to focus on driving maximum value, which is focused on profitability, but we still see lots of upside in new business. We're making some pivots given the COLI changes that we think are gonna help us actually navigate the situation quite well. I just one point on China. I think Anil hit the nail on the head. You know, we do feel good about the changes, the regulatory changes that are being implemented there. We think that they will enable a more sustainable growth in the future. We've been very focused on quality of our products and quality of our distributors. So this is a good thing. Some short-term headwinds there, but in the medium to longer term, we feel again, very positive. You've seen that despite the challenges of COVID and regulation change in 2021, Asia, through its diversity, has still been able to demonstrate outperformance. We've quite frankly grown share in most of our markets, which I think is a hallmark to highlight the strength of our business. Great. Thank you. Thank you. The next question is from Tom MacKinnon from BMO Capital Markets. Please go ahead. Yeah. Just a question with respect to the remittances, up considerably in 2021, versus the 2020 and, you know, versus the trends we saw even prior to 2020. Kind of maybe comments as to what drove that, any details there and, how we might see that continuing, especially given that interest rates continue to rise. Thanks. Great. Thank you, Tom. This is Phil. You're right. It's certainly a strong year for remittances, CAD 4.4 billion. What that reflects is really strong underlying business performance combined with a favorable macroeconomic environment. You asked about the sources of remittances. They do come from all of our geographies and material contributions from all of our geographies. I think what's particularly topical is if we reflect back on a year ago, go back to 2020, that's a period when we had injected capital into Asia. What we've seen in 2021 is that trend reverse, where Asia continues its historic trend of being a net remitter to the group. Just to put a number on that, given your question, the remittances that came from Asia in 2021 were $900 million, and that's very much within the range of what I've seen happen in recent years from Asia. Of course, it is a wide range because of the sensitivity of a number of Asia local bases to interest rates. I think that's more of a normalized environment for Asia. The remainder of the remittances have really come from a balance of our U.S. and Canadian geographies. When I think about that $4.4 billion and the future, although it's a great result, it's not out of line with the range that we've seen in previous years. I think it was 2018, I recall we delivered $4 billion of remittances. I do remain somewhat optimistic about remittances in the medium term, and a couple of reasons for that. One is that we know higher interest rates are a tailwind for remittances from Asia. Also, as we spoke about at Investor Day, when we look at our embedded value and in particular the PVIF within our embedded value and the translation of that PVIF to net assets to cash, there is a really favorable trend that we're looking at there. We're looking at about half of our PVIF being realized as cash over the next 10 years. That provides confidence in our remittance power in the medium term and therefore the progressive dividend policy. Okay, thanks. Thank you. The next question is from Gabriel Dechaine from National Bank Financial. Please go ahead. Good morning. First question on the buyback. I'm sure the technical reason probably tied to the VA transaction there, but there, you know, it was a little bit delayed in terms of getting approval for the buyback. Having said that, are you. I haven't seen any January data, but you're committed to doing the full 3%, maybe not the full 5%, of your capacity in buybacks this year? Thanks, Gabriel. This is Phil. We were really pleased to announce on the first of February the completion of the VA transaction, and on the same day, we announced the approval of the launch of the NCIB following the approvals for that. I think that's all very much routine. We're really—They’re really happy to have approval for a 5% program or up to 5% program. As is normal with buybacks and NCIBs, we will report our progress as we go through this in a routine manner, but also on a quarterly, as a quarterly process, we'll transparently share with this group in this forum what our progress is. I just highlight that when we announced the VA transaction, 15th of November, one of our very important priorities was to neutralize the EPS impact from that transaction. I think that's a very important baseline for the NCIB to neutralize the EPS impacts of that transaction. It would be approximately 3% of the NCIB. The dollar cost of that, of course, will depend upon what the price of the shares are at the time that we repurchase them. Right. On the expenses, you know, congrats on the progress towards that efficiency ratio target 49%. But you're still, and I look at the notes, the financials here, you're running at an expense overrun for a number of years now. Can you quantify, you know, how much that represents as a drag on your earnings, the expense experience loss, I suppose? And then what do you need to do to eliminate it? And is it the, you know, longer-term efficiency ratio target? When does that go away and how? Thanks, Gabriel. This is Phil again. You're right to call out the favorable outcome on expense efficiency ratio. We have hit that 50% threshold, the target that we set ourselves early in 2018. But it doesn't mean that we're done with respect to expense efficiency. You do highlight maintenance expenses and the overrun there. I will point out that within maintenance expenses, we do include in that classification entity sustaining costs, which are not necessarily costs that should be allocated to our underlying businesses, as well as the cost of certain components of our Asia regional office, which doesn't necessarily, again, flow through to each of our businesses. Many of those costs or some of those costs are strategic in nature. Over the course of the coming years, we will continue to focus on expense efficiency. I do think there is further opportunity for us. When you look at the jaws that we're being able to create, the jaws between cost growth and core earnings, there is a substantial gap. That I think does speak to the discipline that we've exercised in recent years. There's certainly more value to be generated there. Is the expense overrun figure something you can quantify? Do I just look at that overhead allocation or is it smaller than that? That's something I have to take away and get back to you on, Gabriel. Okay. Well, thank you. Happy New Year. Thank you. The next question is from Paul Holden from CIBC. Please go ahead. Thank you. Good morning. Want to go back a little bit to the discussion on potential risks related to inflation, I guess. In particular, what that might mean for the long-term care business. Some of your competitors in that business have flagged cost inflation as a potential risk to assumptions and reserving. Just wondering how you're thinking about that. Thanks, Paul. Steve Finch here. I'd start by saying that overall, I've got confidence that our LTC reserves remain appropriate in aggregate with sufficient levels of conservatism. We've seen through the pandemic, we've actually booked gains. Your question is more on what trends might we see in the future. Certainly inflation is in the news broadly, and cost of care inflation is a question out there. We do reflect inflation of cost of care in our long-term assumptions. This is one of the trends that could impact long-term care over time. If we saw higher cost of care, that would result in higher costs if it's higher than our assumptions. We would and we could request appropriate rate increases to offset that. As you've seen, we have a really strong track record of achieving rate increases. As of Investor Day, middle of last year, we disclosed that we had achieved $9 billion at present value of rate increases. We feel good about that. The other thing I'd point out is that there are, you know, I think there's the potential for headwinds like inflation, but there's the potential for tailwinds as well from some of the other trends that we're seeing in long-term care. You know, for instance, what we've seen through the pandemic is, well, one, a hesitancy to receive care. What we've seen is a shift in site of care from facility care towards home care. Home care is on average about 30% less expensive than facility care. If that trend were to continue, that would be a tailwind. I'm just sort of flagging the fact that there, you know, uncertainty around what trends we'll see post-pandemic, but I think there could be pluses and minuses along with our ability to re-rate. Understood. That's that's helpful context. Thanks for that. Second question, and it's related to interest rate impacts. I think you've made it clear that you're effectively immunized on in-force. I think you suggested that on new business because of the portion of par and pass-through, also largely, agnostic to rates. My question would be related to earnings on surplus. That's maybe one area of CTNL that's still rate sensitive. Maybe you can just give us some color there in terms of what higher rates might mean for run rate earnings on surplus. Thanks for the question, Paul. Maybe I start on that one and hand over to Scott, who manages the portfolio. So as you've probably seen in the results, 2020 compared to 2021, we've seen a decline in earnings on surplus. Really what that is triggered by is the lower rate environment that we'd seen in 2020 giving rise to a reset of our IRR allocations to segments that takes place at the beginning of each year. That's why you see the run rate that's allocated to segments go down year on year 2020 compared to 2021, because we set those rates at the beginning of the year and the decline in rates happened during 2020. Now, the extent to which the lower interest rates actually flow through to a lower yield depends upon how much turnover there is in the portfolio. In 2020, we had realized some gains on the AFS portfolio that sits in surplus, and that lowered the yield for 2021. I think where we look from here in terms of how that very stable portfolio, you know, how much of the higher rate environment flows through to yield, it would really depend upon how much turnover there is in that portfolio. Scott, I don't know whether you would like to comment further on that. Sure. Just briefly. I think that's all correct, Phil. You know, our surplus portfolio is fairly long. As you point out, Paul, our you know, accounting earnings are pretty well hedged to higher rates going forward. We do have a fairly long AFS bond portfolio to hedge the economics beyond the accounting. Since it's fairly long, it doesn't on its own turn over very rapidly. Yes, higher rates will ultimately increase surplus earnings, but unless we're actively turning over the portfolio, in the short term you're not gonna see much of that. Got it. Thank you. Thank you. The next question is from David Motemaden from Evercore ISI. Please go ahead. Hi, good morning. Just a question. Phil, you talked about, within the CAD 4.4 billion of remittances, CAD 900 million of that came from Asia. Could you just share the other pieces of that? How much came from the U.S. and how much of that came from Canada? Yeah, David, this is Phil. Broadly speaking, CAD 2 billion was Canada, and that was supported by a favorable macroeconomic environment. The balance was the U.S. Got it. Thanks. How much of that from the U.S. was coming from the VA book that has since been reinsured? Roughly speaking, it was equivalent to the level of profitability, so you know, in the order of $130 million-$140 million, as a ballpark. Okay, great. That's helpful. Maybe a bigger picture question for Roy. You know, obviously good to see the VA transaction, and you know, good to see offsetting the dilution from that, or neutralizing the impact of the lost earnings from that, with the NCIB. I guess I'm wondering, just overall how you're thinking of M&A and specifically, the JV in China, and if that's something you're considering, taking up your share in. A few of your peers, HSBC and Allianz, they've got approval to go up to 100% of their China JVs in the last few months, and Chubb also said they're gonna buy up to close to 90% of their China JV. I'm wondering, is that something you guys are thinking about as well? Yeah, thanks for the question, David. I think firstly, you're right in highlighting our U.S. VA transaction. It's something that we're very proud of executing and completing that deal. We think it's a great transaction, frees up $2 billion worth of capital. The after-tax gain of $750 million or 10x earnings, I think really goes to the heart of demonstrating the conservatism of our assumptions. We really feel very proud of that transaction. For us, the NCIB was about ensuring that we could deploy the capital that we freed up there to make sure that we're driving value for shareholders. We're in a very strong capital position. Phil highlighted that earlier in the presentation, and that puts us in a position where we have significant flexibility. At the same time, we don't need M&A to deliver against our medium-term goals as it relates to earnings, which is, I think, an enviable position to be in. Having said that, we will opportunistically look to deploy capital where it can make sense beyond buybacks and obviously increasing our dividends. We did that through the acquisition of the Aviva book in Vietnam. We did it through the bancassurance agreement with VietinBank in Vietnam. The extension of our banker partnership with Danamon as well is another good example of that. Clearly for us, Asia and WAM are areas where inorganically we would continue to look to deploy capital if the opportunity is right and if we can demonstrate the value accretion. It's easy to announce a transaction, it's another thing to make sure you're creating value from it. Now, specifically to China, we've been in China for a long period of time, both through our JV with Sinochem on the insurance side and with TEDA on the wealth and asset management front. As Anil highlighted earlier, we feel very optimistic about the opportunity that China represents, and we would look to continue to grow our business, our businesses organically there. If the opportunity is present to grow inorganically, we would definitely look at that. At the same time, I would not underestimate the power and value of having a strong partner like we do with Sinochem in China. It's an incredibly valuable asset for us as we navigate, obviously, the local changes in regulatory nuances. So that's a valuable asset. Again, the partnership we have with Sinochem is a tremendous one, and it's contributed to the success we've had in China over the years. If there was an opportunity to increase our stake, we'd definitely look at that. Yeah, I'll probably leave it at that. Thank you for the question, David. Thank you. Thank you. The next question is from Mario Mendonca from TD Securities. Please go ahead. Good morning. I wanna go back to the interest rate discussion. You'll recall that in Q1 2021, Manulife's book value per share was down sequentially over 6%, and the LICAT came under pressure when the yield curve steepened and rates moved higher. Now, a big portion of that related to your AFS portfolio. Is there anything that the company's done since Q1 2021 that would mitigate that effect going forward? Specifically, if we do get a big move in the long end again because of interest rate increases at the short end, if we get that sort of parallel shift, could we be facing that same predicament where the LICAT comes down fairly meaningfully and book value per share declines sharply. Is that scenario still possible for Manulife? Hey, Mario. This is Phil. Maybe I start by touching on the AFS portfolio and then hand over to Steve to talk about the steepening and flattening of the curve. From the AFS portfolio, we haven't made any significant changes to that portfolio since or during the course of 2021. About 80% of our surplus portfolio is held in long AFS bonds. Scott touched on that earlier. We like that for a couple of reasons. One is that you know, investing in U.S. Treasuries allows us to go long in that portfolio, of course, without credit risk. We also like the liquidity of that portfolio, and it does form an important part of our overall risk management program. The movement in value of that portfolio is the inverse of the impact of rates on our liabilities. It doesn't create income statement volatility in itself because, of course, it's an AFS portfolio, so it would be upon realization gains and losses flow through. Where it does create some volatility as you saw in book value per share, but also in the capital ratio. However, when we do look forward to IFRS 17 implementation, one thing that we do expect is that we'll see less variability in the capital ratio as a result of this factor. You know, clearly there's a lot of moving parts. There's more to come on IFRS 17, but we think that is something that will be less acute in the future. Steve, would you like to comment further? Yeah. Thanks, Phil. I think that last point was a key one. The other is that the sensitivity that we had in the LICAT ratio to a rise in interest rates back in terms of what we saw in Q1, that was a 7% change in the LICAT ratio sensitivity back in Q1 2021. That has dropped due to rates and due to you know moderate changes in the hedging program to only 4% now. Almost a 50% reduction in the sensitivity is something I wanted to highlight as well. If I could just follow up on that one thing about the available-for-sale portfolio. Phil, you said that they offer like a good offset or maybe let's call it a hedge against changes in the value of the liabilities or the reserves. The reason I found that explanation it was odd to me is that these available-for-sale securities support surplus. They're in surplus. So why are they relevant then to the liabilities? I would have thought that the liabilities have their own assets matched against them. So what was that reference to the AFS portfolio offsetting changes in the value of the liability? Thanks, Mario. I'll make a start. Scott may wish to comment on this. To the extent we have various options in terms of how we manage interest rate risk. One option is the assets directly backing the liabilities, including the extent to which we hedge. The other option is how we utilize the surplus portfolio. We have chosen to utilize the surplus portfolio to manage overall interest rate risk within the entity. Another option would, of course, be to do more hedging within the liability segment, but this is currently where we are. Scott, I don't know whether you'd like to comment further. Sure. I just point out that, you know, hedging interest rate risk at a life insurance company is pretty complicated. There's a lot of competing objectives. You know, we're trying to reduce the quarterly accounting noise. As I think you know, the accounting is very sensitive to interest rates in current IFRS 4, but not completely. You know, we have the URR out there, which is an indication that there is more sensitivity to interest rates. So if we put all our hedges, our economic hedges in the liability segments, and we do use both cash instruments and derivative instruments there, that would flow through to the accounting, and we would really be overhedged from an accounting perspective. As Phil pointed out, by putting those hedges in surplus and AFS, that you know does not flow through to the accounting results, but is the economic hedge that we're looking for, which is frankly really important. I mean, we saw this in the pandemic when rates went way down. You know, currently people are talking about rates going up, but bad things happen in the world, rates go down. You know, we feel it's very important part of our risk management exercise to be as economically hedged as we can be. Okay. My second question is about IFRS 17. I think there have been a number of occasions on calls like this where I think Phil and Roy, you folks have said, "Hey, this IFRS 17 is accounting." You don't say just accounting, but you do highlight that it really affects the timing and the emergence of profitability, but it really doesn't affect the value or the economics of the company. Now, I always sort of nod in agreement when I hear that, except now that I've read what you've included in your MD&A about IFRS 17 specifically. The company makes reference to things like possibly changing reinsurance. What else do you say? Reinsurance, hedging strategies, investment portfolio. Now, if you start making changes of that nature, then it really does have a meaningful economic effect on the company. Help me reconcile those two messages. One, it's accounting versus two, it's gonna change the way you operate your business. Thanks, Mario, for raising the IFRS 17 topic. This is Phil again. I will specifically address your question in a moment, but given that we've raised IFRS 17, I would like to acknowledge the interest that you and the broader analyst community and shareholder group have, and the demand for more information. We do continue to work through the implementation. We're making good progress, and we look forward to sharing more directional information with you later this year. Now specifically on your point that you picked up on our risk management disclosures in the MD&A. The IFRS 17 is a significant accounting change. While that doesn't directly impact the economics of our business or the way in which we manage the business, I think it does highlight areas where there may be opportunities to optimize under a particular framework. You know, there's potentially greater flexibility to make changes in certain areas. But that doesn't mean we plan to do so. It just highlights that, you know, this different accounting regime may provide a different perspective in certain elements of how we manage the business. But I don't see those as material changes to our business. When I think about earnings in an IFRS 17 environment, one thing that, you know, that we do highlight in those risk management disclosures is the potential for variability. I do want to be balanced and say that as well as the potential for variability, there's also potential for greater stability in an IFRS 17 environment, and that comes from the fact that, for example, new business gains won't be a feature of earnings, they'll be outside of earnings. Also changes in non-economic assumptions will be recorded. Well, the bulk of which would be recorded in the CSM, to the extent there is CSM available. Interest rate movements would be recorded principally within OCI or CSM, reflecting the fact that we are considering adopting the OCI option. I don't think IFRS 17 is all bad news, but we'll have to provide an update, more of an update, as we go through the course of 2022. Yeah. I might just chime in as well, Mario. We definitely stand by our view that the economic fundamentals of our business don't change after an accounting transition like this. It is a huge accounting change though for our industry, and it's one that's been in the making for many years. It would be silly to assume that there wouldn't be tweaks or modifications to the way we execute as a result of it, but there wouldn't be a significant in my mind. I do feel that there are a lot of positives that will come from IFRS 17, to be perfectly frank. The focus on new business, on CSM and the growth of CSM for a fast-growing insurance company like ours is a really big positive. The fact that new business gains aren't going to be capitalized into earnings, but rather capitalized into CSM and then amortized, we think that is a positive, like investment earnings. We will, in due course, provide much more information around the implications of IFRS 17 to our business and the outlook. We feel that there are many positives that come with IFRS 17 that we'll be able to share in more detail at a future point in time. Okay. Thank you very much for that. Appreciate it. Thank you. The next question is from Lemar Persaud from Cormark Securities. Please go ahead. Yeah. Thanks. Good morning. Just thinking about ROE. If you get to your core earnings targets from the highest potential businesses to 75% and Asia to 50%, what could the ROE look like in that scenario out to 2025? I guess where I'm going with this is, if I look at all your targets on efficiency, portfolio optimization, and growth in high potential businesses all together at 13% for 2021, it's not the first time Manulife has hit that ROE level. I guess the bottom line messaging that you're trying to convey isn't that you're going through all this effort to just end up at 13%. Anything you could speak to breaking out of that 13% range would be helpful. Thanks. Yeah. Lemar, this is Roy. Let me start, and I'll ask Phil to chime in with any supplementary thoughts. But you're absolutely right. As we've focused on portfolio optimization and freeing up capital of those businesses that are generating returns that are less than the company average, that is a tailwind to ROE for us. As you highlighted, we continue to grow WAM in Asia, where the ROEs are significantly higher than our average, we're going to start to see an improvement, a consistent improvement in the ROE of our company. Yes, we feel really very optimistic about the outlook as it relates to return on equity, both through the combination of growth and acceleration of our fast-growing businesses that generate higher ROE, but also through the inorganic actions that we've been driving to reduce the capital that's being allocated towards, you know, lower ROE businesses. That's only reinforced through our portfolio optimization and in-force efforts. We are optimistic. At this point in time, we're really not prepared to provide new targets as it relates to ROE, but in due course, that's something that we'll certainly consider. This is Phil. Just to add, we did subtly change our 13% target. We introduced the 13% target in the beginning of 2018, but we did make a subtle change to that to put a plus onto it since then, reflecting the fact that there is upside. When we think about, in particular, you know, Roy talked about Asia and GWAM, but we look at the expected returns on new business in Asia, it's in excess of 20%. That's certainly a tailwind to ROE over the long term and there's upside to that 13% figure. Okay, thanks. Would it be fair to suggest that, as you guys move through the IFRS 17 implementation, you're going to revise these targets? This is Phil again, Lemar. That's a great question. As we proceed through the IFRS 17 implementation and share more directional information with you, what we intend to do as part of that is really look at the key metrics, core earnings and other KPIs that are relevant in an IFRS 17 environment, share with you how we look at defining those metrics, and also indicate what we think that would mean in terms of medium-term financial operating guidance. I think this, ROE is one that's very relevant under IFRS 17. We will provide updates on that. More to come. Great. Thanks. Thank you. The next question is from Nigel D'Souza from Veritas Investment Research. Please go ahead. Thank you. Good morning. I have a few questions for you on policyholder experience, if you could bear with me. The first was on the lapse rates in the quarter. You noted lower lapse rates in North America, and I was wondering if that could perhaps signal a structural shift in lapse rates. Have your customers changed how they value insurance benefits provided by policy given the experience of the COVID-19 pandemic? If lower lapse rates are a possibility, how would that translate into policyholder experience and the potential impact to a LICAT ratio? Thanks, Lemar. It's Steve Finch here. You're right. What we saw when the pandemic started was we saw customers valuing their insurance benefits, and we saw a reduction in lapse rates on protection products in North America by about 20%. It is my expectation that over time, these lapse rates will trend back to pre-pandemic levels. We saw. You know, it's a different shock to the system, but we saw in the global financial crisis a similar phenomenon where customers sort of rethought what their priorities were, but lapse rates did trend back to pre-pandemic levels. That's certainly the expectation. I think we'll need the pandemic to be more in the rearview mirror, not in the news every day. You know, we can't say when that'll be, but that's clearly the expectation. We'll monitor the trends closely. That's helpful. The second question on experience was, long-term care. I believe that was a modest gain this quarter. The question really is on mortality and the hedge of long-term care. Are they different levels of vaccination rates in your long-term care policy block versus your U.S. life policy block? In other words, will long-term care continue to be an effective hedge on, mortality experience due to COVID-19? How do you see that playing out over the longer term? Yeah. Thanks, Lemar. The short answer is yes, we do expect the diversification benefits to continue. What we've seen over the course of the pandemic, we saw significant gains in LTC at the start of the pandemic as the older age population was adversely impacted. We've seen that kind of come back a little bit over time. The expectation is that we will continue to see those mortality diversification benefits. We've seen it. If you look at our MD&A, we actually provide a mortality sensitivity, and that clearly demonstrates the mortality benefits, diversification benefits that we see over time. Nigel, my apologies. I was responding to the wrong name. My apologies. No problem. Lemar's a smart guy, so I'll take that as a compliment. The last question is morbidity. You know, could you maybe shed some light on how morbidity might play out because of the COVID-19 pandemic? There's growing evidence of long COVID and increased morbidity in the U.S., especially in the unvaccinated population. How does that play out for you? Because when I look at your disclosure, you are more sensitive to morbidity assumption changes. But is that due to long-term care policyholder exposure or is that for your overall policyholder exposure? That exposure that you're flagging is to long-term care. When I think about sort of long COVID, you know, we're certainly tracking what the impacts could be over time on mortality. As we just discussed, we have, you know, we have seen those benefits of diversification is still flagged. You know, since the pandemic started, you know, policyholder experience has varied quarter to quarter, but those diversification benefits have been there, CAD 27 million post-tax charge over the course of two years. Then we talked earlier in the call about what we might see in terms of long-term trends. It's really too early to say what morbidity trends might be in the long term. There could be some tailwinds, there could be some headwinds, and we'll have to track that carefully over time. Okay. That's it for me. Thank you. Thank you. There are no further questions registered at this time. I'd like to turn the meeting back over to Mr. Ko. Thank you, operator. We will be available after the call if there are any follow questions. Have a good day, everyone. Thank you. The conference has now ended. Please disconnect your lines at this time, and thank you for your participation.